Tagged as: Biosimilars News

FDA Commissioner Gottlieb Gives Speech on Biosimilars

Earlier today, FDA Commissioner Scott Gottlieb, MD, gave a speech focusing on biosimilars at America’s Health Insurance Plans’ National Health Policy Conference in Washington, D.C.  In his speech, Commissioner Gottlieb highlighted a 2017 study by QuintilesIMS that observed significant cost savings and dramatically expanding patient access in the EU from biosimilars…

Read More

Association of Accessible Medicines: Ensuring the Future of Accessible Medicines in the U.S.

The Association of Accessible Medicines (“AAM”) released a white paper on avoiding shortages and ensuring drug competition for patients in America.  AAM is advocating for the uninterrupted availability of lower-cost generic and biosimilar medicines.  In the paper, AAM asserts that by placing biosimilar medicines on a level competitive playing field with…

Read More

Study Shows that Celltrion’s Infliximab Biosimilar is Comparable to Reference Infliximab and Adalimumab

According to a Celltrion press release, this week investigators presented twelve-month data from a UK-wide, three-year prospective observational study showing comparable efficacy between CT-P13 (Celltrion’s biosimilar infliximab), reference infliximab (Johnson and Johnson’s Remicade), and adalimumab (AbbVie’s Humira). The press release reports that the Personalised Anti-TNF therapy in Crohn’s disease Study…

Read More

Express Scripts and Walgreens Expand Their Group Purchasing to Include Biosimilars

Express Scripts and Walgreens Boots Alliance announced this week that “they are expanding their group purchasing efforts to include the procurement of specialty brand drugs,” including biosimilars.  According to Tim Wentworth, Express Scripts President and CEO, “[s]pecialty medications represent the most costly and complex drugs.  By expanding our efforts with Walgreens Boots Alliance, we…

Read More